Ocugen to Present at 2018 BIO CEO & Investor Conference
MALVERN, Pa., Feb. 6, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City.
Shankar Munsunuri, Ph.D., Chairman, CEO and Co-Founder of Ocugen will highlight Ocugen's leading ophthalmology pipeline, which includes small molecules, highly targeted biologics, and a novel gene therapy platform. Ocugen anticipates entering pivotal clinical trials for its two lead programs in ocular graft versus host disease and chronic dry eye disease in 2018.
Ocugen Presentation Details:
Date: Monday, February 12, 2018
Time: 10:00 AM (Eastern Time)
Location: New York Marriott Marquis, Gilbert Room
An audio webcast will be accessible for 90 days following the presentation via the following link: https://www.ocugen.com/press-releases/
About Ocugen, Inc.
Ocugen, Inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. The Company's lead programs in ocular graft versus host disease (OCU300) and chronic dry eye disease (OCU310) are expected to enter pivotal clinical trials in 2018. OCU300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. Ocugen is also developing novel biologic therapies for retinitis pigmentosa (OCU100) and wet AMD (OCU200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (OCU400). For more information, please visit www.ocugen.com.
Contact:
Ocugen, Inc.
Kelly Morello
kelly.morello@ocugen.com
+1 484-328-4698
View original content with multimedia:http://www.prnewswire.com/news-releases/ocugen-to-present-at-2018-bio-ceo--investor-conference-300593791.html
SOURCE Ocugen, Inc.
